Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/clozapine-and-tardive-dyskinesia-reply-pN9xjUMaNB
- Publisher
- American Medical Association
- Copyright
- Copyright © 1983 American Medical Association. All Rights Reserved.
- ISSN
- 0003-990X
- eISSN
- 1598-3636
- DOI
- 10.1001/archpsyc.1983.01790030117021
- Publisher site
- See Article on Publisher Site
Abstract
Abstract In Reply.— Dr Singer questioned our method of analyzing treatment studies of TD. He specifically mentioned the issues of combining data from open and double-blind studies, using conventional statistics, and not identifying patients with complete remission. Yet, a careful reading of our article shows that data from double-blind and open studies were not combined. Not only were data from the two types of studies presented separately (in Table 1 and Fig 2), but they were also analyzed independently. Because of the shortcomings of conventional univariate comparisons, we used the statistical technique of simultaneous confidence intervals, which took into account possible type I errors resulting from multiple comparisons. Although it would have been helpful to know how many patients had recovered completely, few studies identify patients with complete remission, so such an analysis would have been difficult. The relevance of distinguishing between orofacial and limb dyskinesias is unclear.1,2 With many drugs, the References 1. Baldessarini RJ, Cole JO, Davis JM, et al: Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association . Washington, DC, American Psychiatric Association, 1980. 2. Jeste DV, Wyatt RJ: Understanding and Treating Tardive Dyskinesia . New York, The Guilford Press, 1982. 3. Carroll BJ, Curtis GC, Kokmen E: Paradoxical response to dopamine agonists in tardive dyskinesia . Am J Psychiatry 1977;134:785-789. 4. Caine ED, Polinsky RJ, Kartzinel R, et al: Trial use of clozapine for abnormal involuntary movement disorders . Am J Psychiatry 1979;136:317-320. 5. Gerbino L, Shopsin B, Collora M: Clozapine in the treatment of tardive dyskinesia: An interim report , in Fann WE, Smith RC, Davis JM, et al (eds): Tardive Dyskinesia: Research and Treatment . New York, SP Medical and Scientific Books, 1980, pp 475-489. 6. Gerlach J, Simmelsgaard H: Tardive dyskinesia during and following treatment with haloperidol, haloperidol+ biperiden, thioridazine, and clozapine . Psychopharmacology 1978;59:105-112.Crossref 7. Amsler HA, Teerenhovi L, Barth E, et al: Agranulocytosis in patients treated with clozapine: A study of the Finnish epidemic . Acta Psychiatr Scand 1977;56:241-248.Crossref 8. Cole JO, Gardos G, Tarsy D, et al: Drug trials in persistent dyskinesia , in Fann WE, Smith RC, Davis JM, et al (eds): Tardive Dyskinesia: Research and Treatment . New York, SP Medical and Scientific Books, 1980, pp 419-427. 9. Smith RC, Davis JM: Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine or thioridazine . Life Sci 1976;19:725-732.Crossref 10. Gianutsos G, Moore KE: Dopaminergic supersensitivity in striatum and olfactory tubercle following chronic administration of haloperidol or clozapine . Life Sci 1977;20:1585-1592.Crossref 11. Goldberg SC, Shenoy RS, Julius D, et al: Does long acting depot neuroleptic produce less tardive dyskinesia? Abstracts of the annual meeting of the American College of Neuropsychopharmacology, San Diego, Dec 16-18, 1981, p 74.
Journal
Archives of General Psychiatry – American Medical Association
Published: Mar 1, 1983